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Abstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial 
growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF 
is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant human-
ized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and 
Drug Administration for use in treatment of human solid cancers. Although bevacizumab has 
received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung 
cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of 
other solid tumors. We present the current status and potential use of bevacizumab therapy in 
gastrointestinal cancers.
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Development of bevacizumab
Angiogenesis has been known to be a critical process in tumorigenesis and metastases.1 
Vascular endothelial growth factor (VEGF), a pro-angiogenic factor, binds to two 
receptos VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), activates receptor tyrosine 
kinase (RTK) activity and induces angiogenesis.1 VEGF and its receptors are often 
overexpressed in tumors.2–5 Therefore, targeting angiogenesis was proposed by 
Folkman et al as a therapeutic strategy in the 1970s.6–10 Approaches to block the VEGF 
signaling pathway fall into two categories: anti-VEGF mAB (eg, bevacizumab) and 
RTK inhibitors (RTKi, eg, sunitinib and sorafenib).11–13
Bevacizumab (Avastin®; Genentech/Roche) is a recombinant humanized mAB 
VEGF (VEGF-A for human variant), which theoretically blocks all isoforms of 
VEGFs to bind to VEGF receptors.14 Bevacizumab was approved by the Food and 
Drug Administration (FDA) in 2004 for use in metastatic colorectal cancer (mCRC) 
when used with fluorouracil-containing regimens.15 Its approval was subsequently 
extended to nonsquamous nonsmall cell lung cancer and breast cancer in 2006 
and 2008.16,17
Clinical studies of bevacizumab are underway in early stage colon cancer, unre-
sectable hepatocellular carcinoma (HCC), pancreatic cancer, neuroendocrine tumors, 
nonmetastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian 
cancer, and castrate resistant prostate cancer.18,19 This review article will focus on the 
current use and potential role of bevacizumab in gastrointestinal malignancies.Biologics: Targets & Therapy 2009:3 430
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Colorectal cancer (CRC)
Colorectal cancer, the third-leading cause of cancer-related 
death in the United States, kills approximately 50,000 
patients per year.20 The mortality rate has slightly decreased 
in recent decades. In addition to public awareness and early 
detection, effective adjuvant therapies are significant players 
in improving the outcome.
Bevacizumab in first-line therapy  
for advanced CrC (Table 1)
Four cytotoxic chemotherapy regimens are generally 
accpeted as first line therapies for mCRC: fluouracil and 
leucovorin (5-FU/LV), 5-FU/LV/oxaliplatin (FOLFOX), 
5-FU/LV/irinotecan (FOLFIRI), and capecitabine/oxaliplatin 
(CapeOX, also named XelOX).21–25
The first phase II trial investigating the safety and efficacy 
of bevacizumab in the first-line treatment of mCRC was 
conducted in 2003.26 One hundred and four patients with 
untreated mCRC randomized to receive one of the three 
regimens: 5-FU/LV (control arm), 5-FU/LV plus low-
dose bevacizumab (5 mg/kg) and 5-FU/LV plus high-dose 
bevacizumab (10 mg/kg). The addition of bevacizumab to 
5-FU/LV increased the response rate (RR), prolonged median 
time to disease progression (TTP), and median overall 
survival (OS) (Table 1). Surprisingly, the higher dose did not 
correlate with higher efficacy. Bevacizumab-related toxicities 
were thrombosis, hypertension, proteinuria, and epistaxis.
Pooled results from several phase II studies have subse-
quently demonstrated that adding bevacizumab to 5-FU/LV 
regimens improved OS in untreated mCRC from 14.6 to 
17.9 months.26–29
The encouraging phase II result led to randomized large 
phase III trials with the goal of incorporating bevacizumab 
into first-line therapy for mCRC. ‘Low-dose’ bevacizumab 
(5 mg/kg) was used in combination with irinotecan, 5-FU, 
and LV (IFL) in the pivotal phase III trial.30 Eight hundred and 
thirteen patients with untreated mCRC received either IFL 
plus placebo, or IFL plus bevacizumab. This trial includes 
approximately 20% of all patients with diagnosis of rectal 
cancer. IFL plus bevacizumab combination was proved to 
be superior to IFL plus placebo not only in RR (44.8% vs 
34.8%, P = 0.004) but also in OS with an absolute benefit 
of 4.7 months (20.3 vs 15.6 months, P  0.001), as well as 
progression-free survival (PFS) with an absolute benefit of 
4.4 months (10.6 vs 6.2 months, P  0.001). Safety data in 
this trial revealed manageable hypertension related to beva-
cizumab, but no thromboembolic events or proteinuria.
This was the first time that a large trial confirmed the role 
of bevacizumab in prolonging OS in mCRC in a clinically 
meaningful way. This trial led to FDA approval of bevaci-
zumab in first-line setting in combination with fluorouracil-
based chemotherapy.15
The efficacy of bevacizumab in irinotecan-containing 
regimens was also tested in phase III trial. Fuchs and 
colleagues initially designed a phase III trial (BICC-C) to 
compare the efficacy of 3-irinotecan containing regimens in 
the first-line treatment of mCRC: irinotecan plus infusional 
(FOLFIRI), bolus (mIFL) or oral fluoropyrimidine 
(CapeIRI).31 430 patients were enrolled into this trial. 
After FDA approved bevacizumab in 2004, this trial was 
amended to add 117 patients to receive either FOLFIRI plus 
bevacizumab (n = 57) or mIFL plus bevacizumab (n = 60), 
no further enrollment was made to CapeIRI arm due to toxicity 
concerns.31,32 After a median follow-up of 34.4 months, 
the data demonstrated superior activity of FOLFIRI plus 
bevacizumab over mIFL plus bevacizumab in terms of 
OS (28 vs 19.2 months; P = 0.037), and 1-year survival 
rate (87% vs 61%; respectively). However, both regimens 
achieved similar overall response rate (57.9% for FOLFIRI 
plus bevacizumab and 53.3% for mIFL plus bevacizumab). 
This trial proved the efficacy of bevacizumab in combination 
with irinotecan-containing regimens, more importantly, this 
trial established the standard of care of infusional 5-FU for 
the irinotecan-based regimen.
Another large study, NO16966 which originally designed 
to compare the noninferiority of CapeOX to FOLFOX-4, 
Table 1 Summary of the phase II trial investigating two doses of bevacizumab plus 5-FU/LV
  5-FU/LV  5-FU/LV + bevacizumab  
(5 mg/kg)
5-FU/LV + bevacizumab 
(10 mg/kg)
response rate 17% 40% (*P = 0.029) 24% (*P = 0.434)
mTTP 5.2 months 9.0 months (*P = 0.005) 7.2 months (*P = 0.217)
mOS 13.8 months 21.5 months (*P = 0.137) 16.1 months (*P = 0.582)
*Compared with 5-FU/LV control arm.
Abbreviations: mOS, median overall survival; mTTP, median time to progression; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 5-FU/LV/oxaliplatin; mFOLFOX, modified 
FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; CapeOX, capecitabine/oxaliplatin; IFL, irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 431
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was modified to test the additional benefit of bevacizumab 
in first-line therapies after the aforementioned phase III trial 
demonstrated superiority of adding bevacizumab into first-line 
cytotoxic chemotherapy. Therefore, this trial included 4 arms 
in order to compare the efficacy of CapeOX and FOLFOX-4 
with or without bevacizumab.33 A total of 1401 patients were 
enrolled. Bevacizumab arms achieved significantly longer 
PFS compared with non-bevacizumab arms (9.4 vs 8.0, 
hazard ratio [HR] = 0.83; 97.5% confidence interval [CI], 
0.72 to 0.95; P = 0.0023). However, the addition of bevaci-
zumab did not affect OS (21.3 vs 19.9 months, HR = 0.89; 
97.5% CI, 0.76 to 1.03; P = 0.077). The authors argued the 
lack of OS benefit might be caused by early discontinuation 
of bevacizumab. Nevertheless, this trial is still considered a 
clinically meaningful study. The National Comprehensive 
Cancer Network of the United States (NCCN) recommend 
bevacizumab be added with front-line oxaliplatin-containing 
regimens for initial treatment.
Besides FOLFOX-4, bevacizumab was also investigated 
in combination with other three oxaliplatin-containing regi-
mens in Three Regimens of Eloxatin Evaluation (TREE)-2 
study.34 In this study, oxaliplatin with infusional, bolus, and 
oral fluoropyrimidine with or without bevacizumab were 
evaluated as first-line treatment for mCRC. The addition 
of bevacizumab to all three regimens improved overall RR 
and prolonged OS compared with their comparators. Among 
these three regimens, oxaliplatin plus infusional 5-FU/LV 
(FOLFOX) plus bevacizumab appeared to be superior to the 
other two (Table 2).
Bevacizumab in combination with another oxaliplatin-
containing regimen, modified (m) FOLFOX-7, was 
investigated CONcePT (Combined Oxaliplatin Neurotoxicity 
Prevention Trial) Trial.35 This trial was designed to optimize 
oxaliplatin dose in order to reduce neurotoxicity. There-
fore, the major two arms are alternating mFOLFOX-7 with 
5-FU/LV plus bevacizumab, and continuous mFOLFOX-7 
plus bevacizumab. The primary endpoint was time to treat-
ment failure. CONcePT also measured the effect of intrave-
nous calcium and magnesium supplement on neurotoxicity 
prevention. After 140 patients with mCRC were enrolled, the 
first interim analysis suggested calcium/magnesium supple-
ment might be negatively impacting anti-tumor activity of 
chemotherapy. Therefore, this trial was closed early in June 
2007. However, an independent radiology review demon-
strated that response was not affected by calcium/magnesium 
supplementation. The intermittent oxaliplatin arm showed 
significant improvement of PFS and time to treatment failure 
(TTF) when compared with the continuous oxaliplatin 
arm (12 vs 7.3 months, P = 0.03; and 5.6 vs 4.2 months, 
P = 0.003; respectively). This trial proved the convincing 
benefit of intermittent oxaliplatin over continuous oxalipla-
tin. However, the role of bevacizumab was impossible to be 
investigated given both arms contain same dose/schedule 
of bevacizumab.
Bevacizumab in second-line therapy  
for advanced CrC
Bevacizumab was also tested in mCRC in combination 
with oxaliplatin-based regimen in second-line setting. 
In the Eastern Cooperative Oncology Group (ECOG) trial 
(E3200), 829 patients with previously treated CRC but 
without prior oxaliplatin or bevacizumab exposure were 
Table 2 Summary of trials investigating bevacizumab in first-line setting for metastatic colorectal cancer
Trial/Reference No. of patients Regimens ORR mPFS (months) mOS (months)
Hurwitz trial30 813 iFL + bevacizumab vs iFL + placebo 44.8% vs 34.8% 
(P = 0.004)
10.6 vs 6.2 (P  0.001) 20.3 vs 15.6 (P  0.001)
BICC-C31,32 117 FOLFiri + bevacizumab (n = 57)  
vs miFL + bevacizumab (n = 60)
57.9% vs 53.3% 11.2 vs 8.3  
(not statistically 
significant)
28 vs 19.2% (P = 0.037)
NO1696633 1401 CapeOX/FOLFOX4 + placebo 
(n = 701) vs CapeOX/FOLFOX-4 + 
bevacizumab (n = 699)
49% vs 47% 8.0 vs 9.4 (P = 0.023) 19.9 vs 21.3 (P = 0.077)
TREE-234 213 mFOLFOX + bevacizumab (n = 71)  
vs bFOL + bevacizumab (n = 70)  
vs CapeOx + bevacizumab (n = 72)
52% vs 39% vs 46% 9.9 vs 8.3 vs 10.3 26.1 vs 20.4 vs 24.6
CONcePT35 140 mFOLFOX-7 + bevacizumab vs 
mFOLFOX-7/5-FU/LV + bevacizumab
Not available 12 vs 7.3 (P = 0.03) Not available
Abbreviations: ORR, overall response rate; mPFS, median progression-free survival; mOS, median overall survival; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 5-FU/LV/
oxaliplatin; mFOLFOX, modified FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; CapeOX, capecitabine/oxaliplatin; IFL, irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 432
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randomized to 3 arms at 1:1:1 ratio: FOLFOX-4 plus beva-
cizumab, FOLFOX-4, or bevacizumab alone.36 The dose 
of bevacizumab chosen was 10 mg/kg although a phase II 
trial concluded that 5 mg/kg dose was more effective than 
10 mg/kg dose.26 The authors of E3200 trial believed that the 
effect of bevacizumab was dose-dependent and 10 mg/kg 
should be more active in combination with chemotherapy. 
FOLFOX-4 plus bevacizumab treatment in irinotecan-refrac-
tory mCRC demonstrated not only an improved overall RR 
but also statistically significant survival benefit compared 
with FOLFOX-4 or bevacizumab alone (Table 3).
Interestingly, prior to the publication of this trial, the 
study of FOLFOX-4 as first-line therapy for mCRC was 
just accepted as the standard of care for initial treatment in 
the United States.25 Therefore, the E3200 trial also proved 
the anti-tumor effect of FOLFOX-4 with or without bevaci-
zumab in second-line setting after irinotecan failure. More 
importantly, bevacizumab in combining with cytotoxic 
chemotherapy provided additional response and survival 
benefit.
Similarly, bevacizumab was investigated in combination 
with an irinotecan-based regimen in second-line setting. 
Bowel Oncology and Cetuximab Antibody (BOND)-1 study 
conducted by Cunningham et al had established the role of 
irinotecan and epithelial growth factor receptor (EGFR) 
monoclonal antibody (mAb)–cetuximab in second-
line setting.37 The BOND-2 study was subsequently 
designed to evaluate any benefit of adding bevacizumab to 
irinotecan–cetuximab combination therapy.38 Until now, this 
was the first and remained the only trial showing that concur-
rent use of dual-mAb therapy did not increase toxicity but 
improved PFS. Unfortunately, these results were not shown 
in the large trials Panitumumab Advanced Colorectal Can-
cer Evaluation (PACCE) or CApecitabine, IRinotecan, and 
Oxaliplatin in advanced CRC (CAIRO)-2 studies,39–52 both 
of which showed unacceptable toxicities when 2 monoclonal 
antibodies were administered in combination with cytotoxic 
chemotherapy. Dual biologic therapy will be discussed in 
another section in this review.
There are well-accepted convincing data of incorporating 
bevacizumab with irinotecan-, oxaliplatin-based regimens 
as first-line or second-line therapies for mCRC. However, 
many clinical questions remained unanswered, such as the 
role of bevacizumab maintenance, or continuation of beva-
cizumab in second- or third-line settings in patients who had 
prior exposure to bevacizumab-containing regimens. The 
DREAM (Double Reintroduction with Erlotinib and Avastin 
in Metastatic CRC) trial was designed to evaluate the role of 
bevacizumab with or without erlotinib as maintenance treat-
ment.43 Patients were treated with 6 cycles of FOLFOX-7 plus 
bevacizumab or 6 cycles of CapeOX-4 plus bevacizumab, 
then maintenance bevacizumab with or without erlotinib, 
followed by reinduction of FOLFOX-7 or CapeOX plus 
bevacizumab on disease progression. The primary endpoints 
are PFS and OS. We hope the final data will be able to answer 
the above questions.
Current consensus does not support the continuation 
of bevacizumab if a patient has already had it in first-line 
therapy, because of lack of supporting data.
Dual-biologic therapy in mCRC
In theory, targeting two separate pathways such as VEGF 
and EGF pathways simultaneously potentially produces 
higher anti-tumor effect. However, in reality, we have seen 
extremely dangerous toxicities in several trials using 2 mAbs 
or 1 mAb plus 1 RTKi.39–42
Combination of bevacizumab and eGFr mAb
The first trial combining bevacizumab with another biologic 
agent was BOND-2 study.38 A regimen of irinotecan, 
cetuximab plus bevacizumab was investigated. The efficacy 
data demonstrated that the dual-biologic regimen potentially 
provided survival benefit compared with mono-biologic regi-
men (such as irinotecan/cetuximab) and could be considered 
as a second-line option for irinotecan-refractory mCRC.
However when a similar idea was tested in large trials, an 
unexpectedly high incidence of severe toxicity emerged. The 
PACCE trial was designed to investigate the role of combin-
ing anti-EGFR and anti-VEGF antibody with chemotherapy 
as first-line treatment in patients with advanced CRC.39,40 
In this study, FOLFOX or FOLFIRI plus bevacizumab with or 
without panitumumab, an anti-EGFR mAb, were compared. 
The rationale for this design was based on preclinical stud-
ies suggestive of additive anti-tumor effect of targeting on 
2 separate pathways. The data from the PACCE trial were 
Table 3 Summary of the efficacy data of E3200 trial36
FOLFOX-4 +  
bevacizumab 
(n = 286)
FOLFOX-4 
(n = 291)
Bevacizumab 
(n = 243)
P value
Orr 22.7% 8.6% 3.3% P  0.001
PFS 7.3 months 4.7 months 2.7 months P  0.001
OS 12.7 months 10.8 months 10.2 months P = 0.0011
Abbreviations: ORR, overall response rate; PFS, progression-free survival; OS, overall 
survival; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 5-FU/LV/oxaliplatin; mFOLFOX, 
modified FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; CapeOX, capecitabine/oxaliplatin; IFL, 
irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 433
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certainly surprising. The dual-biologic target therapy did not 
provide any benefit to the efficacy but significantly increased 
the incidence of severe gastrointestinal (GI) toxicity such as 
diarrhea and infections.
CAIRO-2 study conducted by the Dutch Colorectal 
Cancer Group is another large phase III trial attempting to 
evaluate the effectiveness of dual biologic therapy.41 This is a 
well-designed, multicenter clinical trial in which 736 patients 
with previously untreated mCRC were randomly assigned 
to receive capecitabine, oxaliplatin, and bevacizumab (CB) 
with or without cetuximab (CBC) every 3 weeks. Besides 
the use of bevacizumab, there are 2 differences between 
CAIRO-2 and PACCE: panitumumab was changed to a more 
commonly used anti-EGFR antibody, cetuximab; the back-
bone conventional chemotherapy switched from FOLFOX/
FOLFIRI to CapeOX. The final results of CAIRO-2 were 
recently published (Table 4).42 The results were somewhat 
expected – reduced survival length plus overwhelming 
toxicities.
The two large trials, PACCE and CAIRO-2, both showed 
significant toxicity without any clinical benefit when combin-
ing 2 monoclonal antibodies with cytotoxic chemotherapy. 
Until now, there is no clear explanation for the observed 
negative effect. Therefore, the National Cancer Institute 
(NCI) suspended another ongoing large trial being conducted 
by the Cancer and Leukemia Group B (CALGB) and South 
West Oncology Group (SWOG).44 The study was designed 
to answer the question of whether 2 antibodies are superior 
to single antibody when combined with chemotherapy. The 
current consensus is that combined biologic therapy with 
anti-EGFR and anti-VEGF antibodies should not be used 
outside an appropriate clinical trial setting. We have known 
that neither cetuximab nor panitumumab would provide any 
response benefit in KRAS mutant CRC. Nevertheless, the 
negative outcome could not be all attributed to the KRAS 
status.
Combination of bevacizumab and erlotinib
Bevacizumab and erlotinib were combined with FOLFOX 
for first-line treatment of mCRC in a phase II study.45 All 
35 patients initially enrolled for intention to treat were off 
study secondary to intolerable toxicity rather than disease 
progression. Major toxicities included rash, diarrhea, and 
neuropathy. Interestingly, despite premature termination 
of this trial because of toxicity, 12 patients achieved objec-
tive response, and 1 patient even had complete response. 
However, interpreting these efficacy data in an early closed 
trial would be challenging. Overall this double-target therapy 
combination was believed to be too toxic.
Bevacizumab in CrC adjuvant setting
Should we extrapolate the promising data of bevacizumab 
in advanced CRC into adjuvant setting? The answer to 
this question is no for now. Clearly current data from the 
National Surgical Adjuvant Breast and Bowel Project C-08 
trial (NSABP C-08) did not support the use of bevacizumab 
in the adjuvant setting given lack of survival benefit. Allegra 
and colleagues published the safety data.46 This randomized 
phase III trial was designed to compare modified FOLFOX-6 
(every 2 weeks for 12 cycles) with bevacizumab vs without 
bevacizumab. For the nonbevacizumab arm, patients received 
standard mFOLFOX-6 for a total of 12 cycles, while patients 
in the bevacizumab arm were offered bevacizumab mainte-
nance after completion of 12 cycles of mFOLFOX-6 plus 
bevacizumab (Figure 1).
The safety data were obtained from 2647 patients with 
surgically resected stage II/III colon cancer. The dose of 
bevacizumab was 5 mg/kg every 2 weeks. The primary 
endpoint is 3-year disease-free survival (DFS). Demographic 
factors were well balanced. Twenty-five percent of patients 
had stage II disease in each arm.
The safety data revealed virtually identical incidence of 
grade 4 toxicities in both arms (15.2% and 15.0%, respec-
tively). Bevacizumab arm did show significantly higher rate 
of several toxicities; however, those previously concerned 
toxicities such as GI bleeding, perforation, or ischemic 
events were not statistically different when compared with 
the nonbevacizumab arm (Table 5).
Following the overall acceptable safety data, the final 
survival data were subsequently presented at the 2009 ASCO 
annual meeting.47 Surprisingly, no PFS benefit was observed 
Table 4 Toxicity and efficacy profile of CAIRO-2 study41
  CB  
(n = 368)
CBC  
(n = 368)
P value
Any grade 3 or above toxicity (%) 73.2 81.7 0.006
Any cutaneous event (%) 20.8 39.1 0.001
Diarrhea (%) 19.1 26% 0.03
response rate (%) 50 52.7 0.49
mPFS (months) 10.7 9.4 0.16
mOS (months) 20.3 19.4 0.49
Disease control rate (%) 94 94.6 0.72
Abbreviations: CB, capecitabine, oxaliplatin and bevacizumab; CBC, capecitabine, 
oxaliplatin and bevacizumab with or without cetuximab; mPFS, median progression-free 
survival; mOS, median overall survival; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 
5-FU/LV/oxaliplatin; mFOLFOX, modified FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; 
CapeOX, capecitabine/oxaliplatin; IFL, irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 434
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with the addition of bevacizumab regardless of disease 
stage (Table 6). Therefore, use of bevacizumab in the colon 
adjuvant setting cannot currently be recommended in the 
absence of efficacy data.
Pancreatic cancer
Pancreatic cancer is the fourth leading cause of cancer related 
death in the US.48 The prognosis of pancreatic cancer depends 
on the resectability of primary tumor; however, more than 
80% of patients have locally advanced disease or metastases 
upon diagnosis. Single agent gemcitabine remains the only 
universally accepted effective palliative treatment that not 
only provides clinical benefit but also prolongs OS.49
Since the approval of gemcitabine in 1997 by the FDA, 
numerous combinations using gemcitabine as a backbone 
were investigated in many clinical trials. The combination 
of erlotinib with gemcitabine reached statistical significance 
in terms of OS, leading to FDA approval of erlotinib in 
advanced pancreatic cancer (APC) in November 2005.50
Use of bevacizumab in phase ii  
clinical trials
Bevacizumab was tested in several combinations with cyto-
toxic chemotherapy in phase II trials. Kindler et al published 
the first phase II trial of bevacizumab in combination with gem-
citabine in untreated APC as first-line therapy.51 Gemcitabine 
(1000 mg/m2) was given on days 1, 8, and 15 every 28 days; 
bevacizumab (10 mg/kg) was given on days 1 and 15 after 
gemcitabine. Fifty-two patients with confirmed APC were 
treated. Eleven patients (21%) had partial responses, and 
median OS and PFS were 8.8 and 5.4 months, respectively. 
These results appear encouraging, but the toxicity profile was 
worrisome. In this 52-patient trial, the incidence of bowel 
perforation was 8%, which was strikingly high compared to 
the observations in other colorectal trials.
The North Central Cancer Treatment Group (NCCTG) 
investigated bevacizumab in combination with gemcitabine 
Stage II or III colon cancer
(n = 2710) 
Stratification based on number of positive lymph nodes 
Randomization (1:1) 
mFOLFOX-6 × 12 
cycles
(n = 1356) 
mFOLFOX-6 × 12 cycles, 
bevacizumab maintenance 
× 14 cycles 
(n = 1354) 
mFOLFOX dose:
LV 400 mg/m
2 iv 
5-FU 400 mg/m
2iv
5-FU 2400 mg/m
2 over 
46 hours
Oxaliplatin 85 mg/m
2 iv 
Figure 1 Schema of NSABP C-08 trial.46,47
Table 5 Summary of severe toxicity data of NSABP C-08 trial45
Grade 3 or above 
adverse events
mFOLFOX + 
bevacizumab 
(n = 1326)
mFOLFOX 
alone  
(n = 1321)
P value
Hypertension 12% 1.8% 0.0001
wound complications 1.7% 0.3% 0.001
Pain 11.1% 6.3% 0.0001
Proteinuria 2.7% 0.8% 0.001
Neuropathy 16.7% 14.4% NS
Gi perforation 0.3% 0.2% NS
Any hemorrhage 1.9% 1.9% NS
Peripheral arterial 
ischemia
0.0% 0.2% NS
Abbreviations: GI, gastrointestinal; NS, not statistically significant; 5-FU/LV, 
fluouracil and leucovorin; FOLFOX, 5-FU/LV/oxaliplatin; mFOLFOX, modified 
FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; CapeOX, capecitabine/oxaliplatin; IFL, 
irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 435
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and oxaliplatin,52,53 a combination that regained attention 
after several pooled- and meta-analyses demonstrated a 
small benefit for selected patients with good performance 
status.54–57 Objective RR was 11.3% in a total of 80 eligible 
patients. The 6-month survival was 65.0%; median OS and 
PFS were 8.1 and 5.7 months, respectively.52,53
Bevacizumab with or without docetaxel was tested by 
Astsaturov and colleagues,58 although the rationale of this 
trial was not convincing given the minimal activity of taxanes 
in pancreatic cancer in general. Bevacizumab was given at 
10 mg/kg every 2 weeks alone or with docetaxel at 35 mg/m2 
weekly for 3 weeks followed by 1 week off. Fifteen out of 
30 patients experienced severe adverse events including 
5 deep venous thromboses and 2 bowel perforations. There 
was no difference in terms of PFS or OS in either arm. The 
results of this trial only confirmed an already-known fact that 
taxanes generally do not have an anti-tumor effect in APC. 
In addition, single-agent bevacizumab was also proved to 
lack efficacy in this aggressive disease.
Overall, all the above-mentioned phase II trials except 
the combination of bevacizumab and gemcitabine failed to 
demonstrate any convincing benefit compared with historical 
gemcitabine monotherapy.51–53,58,59
Use of bevacizumab in phase iii  
clinical trials
The high response rate in phase II results for bevacizumab plus 
gemcitabine provided the rationale for a phase III CALGB 
80303 study, in which gemcitabine with or without bevaci-
zumab were compared.60 Six hundred and two patients with 
APC were enrolled into this large placebo-controlled trial, ran-
domized for patients to receive gemcitabine plus bevacizumab 
(GB) versus gemcitabine plus placebo (GP). The primary 
endpoint was OS, secondary endpoints were RR, duration of 
response, PFS, and toxicity. Median OS and PFS of GB/GP 
were 5.8/6.1 and 4.9/4.7 months, respectively. RR and 1-year 
survival rate failed to reach statistical difference.
The comparison of phase II and phase III data revealed 
that difference in performance status, adjuvant treatment, 
and/or previous thrombotic events might be able to explain 
the negative outcome. Toxicity profile was not substantially 
different from any other large bevacizumab trials, including 
hypertension (8%), GI perforation (0.4%), GI bleeding (3%), 
proteinuria (4%), and venous thrombosis (9%). Nevertheless, 
the addition of bevacizumab to gemcitabine did not offer any 
meaningful clinical benefit.
Another phase III trial of bevacizumab was the Tarceva ± 
Avastin in APC (AViTA) trial, which was unfortunately 
another negative trial.61 AViTA aimed to explore the supe-
riority of gemcitabine/erlotinib plus bevacizumab over 
gemcitabine/erlotinib plus placebo in APC. The biologic 
rationale for such a design came from retrospective studies 
demonstrating an adverse correlation between overexpression 
of EGFR and VEGF in pancreatic cancer with survival.62,63
OS was the primary objective, PFS, disease control 
rate, and toxicity were secondary objectives. Six hundred 
and seven patients with metastatic pancreatic cancer were 
randomized to receive gemcitabine/erlotinib with or without 
bevacizumab as initial therapy (Figure 2).
Although DFS (from 3.6 to 4.6 months) met statistical sig-
nificance (HR 0.73, P = 0.0002), no significant prolongation 
but a trend toward OS benefit was seen in the bevacizumab 
arm (7.1 vs 6.0 months, HR 0.89, P = 0.2087). The authors 
believe this 1-month disease-free survival benefit suggests 
that a subset of metastatic patients might derive more benefit 
from anti-angiogenic therapy than others. However, how to 
identify these subgroup patients remains unclear.
Hepatocellular carcinoma (HCC)
HCC is a highly vascularized tumor with poor prognosis. 
Its incidence is rising in Europe and US as a result of the 
high prevalence of hepatitis C.48 Surgical resection and liver 
transplantation are the effective curative interventions only 
for local resectable disease; however, the majority of cases 
present with advanced stage or metastatic stage. Sorafenib is 
the only standard of care for advanced HCC, modest benefit at 
the sacrifice of toxicity made the development of novel agents 
urgent.64 VEGF is found to be aberrantly expressed in HCC 
and plays a critical role in tumorigenesis as well as disease 
progression.5 The use of anti-angiogenic agents appears to be 
a promising approach in view of the highly vascular nature 
of this tumor. Several early phase trials have investigated the 
role of bevacizumab in the treatment of HCC.
Finn et al established a mouse model to assess the anti-
angiogenic effect of bevacizumab. Hep 3B cells, a human 
Table 6 Survival data of NSABP C-0847
mFOLFOX-6 +  
bevacizumab  
(n = 1334)
mFOLFOX-6 
alone  
(n = 1338)
Hazard 
ratio  
(HR)
P value
DFS (3-yr) 77% 75.5% 0.89 0.15
Stage ii 87% 85% 0.82 0.35
Stage iii 74% 72% 0.90 0.25
Abbreviations: DFS, disease-free survival; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 
5-FU/LV/oxaliplatin; mFOLFOX, modified FOLFOX; FOLFIRI, 5-FU/LV/irinotecan; 
CapeOX, capecitabine/oxaliplatin; IFL, irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 436
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HCC cell line, were inoculated into the livers of severe 
combined immunodeficient (SCID) mice under anesthesia.65 
Bevacizumab at 5 mg/kg was administered intraperitoneally 
twice weekly into half of the mice. Serum alpha-fetoprotein 
(AFP) and VEGF level were measured as surrogate markers 
for response, while tumors were harvested for vascular 
study such as immunohistochemical staining of the endo-
thelial marker CD31. Bevacizumab significantly decreased 
microvessel density in tumors and decreased serum AFP 
level. These preclinical data led to bevacizumab being tested 
in human subjects.
Forty-six patients with unresectable nonmetastatic HCC 
were enrolled into a phase II study.66 12 patients received 
bevacizumab at 5 mg/kg, while the other patients received 
a higher dose at 10 mg/kg every 2 weeks until disease 
progression or treatment-limiting toxicity. Overall objective 
RR was 13%. Median PFS was 6.9 months (95% CI 6.5 
to 9.1 months). More than 50% of patients survived more 
than 1 year, more than 25% survived beyond 2 years. The 
efficacy results were encouraging, but hypertension, bleed-
ing, and thrombotic events remain the major safety concern 
for bevacizumab treatment.
Zhu et al conducted a phase II trial to examine the 
efficacy of gemcitabine and oxaliplatin plus bevacizumab 
(GEMOX-B) in unresectable or metastatic HCC.67 The 
schedule was bevacizumab 10 mg/kg administered every 
14 days, fixed dose rate gemcitabine 1000 mg/m2 every 
14 days, and oxaliplatin 85 mg/m2 on the following day after 
gemcitabine. Thirty patients were eligible for efficacy 
analysis. Six patients achieved objective response on imaging 
studies according to RECIST; median PFS and OS were 
5.3 and 9.6 months, respectively. Severe toxicities related 
to treatment were bone marrow suppression, abnormal liver 
function, hypertension, and fatigue. The benefit derived from 
this regimen appears to be comparable with that of sorafenib, 
but a larger trial is warranted for further investigation.
The effect of bevacizumab on angiogenesis was examined 
by the same research group utilizing computed tomography 
perfusion scan.68 Bevacizumab induced a significant decrease 
in tumor blood flow, blood volume, and permeability 
in HCC.
Bevacizumab and erlotinib combination was also inves-
tigated in advanced or metastatic HCC at phase II level.69 
This regimen consists of bevacizumab 10 mg/kg every 
14 days and erlotinib 150 mg oral daily, for each 28-day 
cycle. The primary endpoint of this phase II study was PFS 
at 16 weeks. Of 40 patients, 62.5% survived beyond 16 weeks 
without evidence of progression. Ten patients achieved a 
partial response, while median PFS and OS were 9.1 and 
15.9 months, respectively. The dual-biologic agent strategy 
showed very promising anti-tumor activity in HCC. More 
importantly, toxicity profile of this combination regimen 
was acceptable. More recently, an updated report was 
presented at the 2009 ASCO annual meeting.70 With a total 
of 57 patients, overall RR was 28%, and median PFS and 
OS were 7.9 months and 12.8 months, respectively. PFS at 
16 weeks was 73%. Currently, a multi-institution randomized 
phase II trial is ongoing to further characterize the clinical 
benefit of the combination.
Among other regimens, the combinations of bevacizumab 
and mammalian target of rapamycin (mTOR) inhibitors appear 
encouraging. Bevacizumab and rapamycin combination 
Advanced pancreatic cancer
(n = 607) 
Randomization (1:1) 
Placebo + gemcitabine + 
erlotinib (n = 301) 
Bevacizumab +
gemcitabine + erlotinib
(n = 306)   
Gemcitabine 1000
mg/m2/week × 3, 
iv; erlotinib 100 mg/day
oral; bevacizumab
5 mg/kg q2 weeks, 
iv; each cycle 28 days
Figure 2 Schema of AviTA trial.61Biologics: Targets & Therapy 2009:3 437
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offered promising anti-tumor activity in an orthotopic 
intrahepatic xenograft mouse model.71 Bevacizumab and 
everolimus combination is also being tested in human 
subjects.72
Cholangiocarcinoma  
and gallbladder cancer
Unlike other GI malignancies, there is very limited 
experience with the use of bevacizumab in cholangiocar-
cinoma or gallbladder cancer. A Taiwan oncology group 
reported an interesting case in 2006. An elderly patient with 
cholangiocarcinoma achieved quick response in liver metas-
tases after being treated with cisplatin, 5-FU, leucovorin plus 
bevacizumab.73 However, this is just a single case observa-
tion outside a clinical trial setting. In addition, the effect of 
tumor shrinking can hardly be attributed to bevacizumab 
anti-angiogenic effect alone. More prospective studies should 
address whether this combination can be an appropriate 
option for advanced biliary duct cancer.
Given the popularity of the double pathway blocking 
approach, especially the combination of bevacizumab 
and erlotinib, Holen and colleagues also investigated this 
combination in previously untreated advanced gallbladder 
cancer or cholangiocarcinoma. The data were presented at 
the 2008 ASCO annual meeting.74 Twenty-nine patients 
were eligible for enrollment; 3 out of 17 (17.6%) evalu-
able patients achieved partial response (PR). The projected 
accrual is not completed yet for this trial, and final efficacy 
data are therefore pending. The data are currently being 
validated in other larger trials (Table 7). Several other trials 
are ongoing to investigate the efficacy of bevacizumab 
with cytotoxic agents, and/or radiation in biliary duct and 
gallbladder cancer.
Gastric and esophageal cancer
Gastric cancer is one of the leading causes of cancer-related 
death in the US. Median OS for metastatic or unresectable 
disease is usually less than 10 months. Despite response 
rates of 30% to 60% to combination chemotherapy, response 
duration is usually 4 to 6 months and 24-month survival is 
5% to 10%. VEGF overexpression was also found in gastric 
cancer and was associated with poor prognosis.75,76 This 
suggests that anti-VEGF therapy might have also have an 
effect on gastric cancer. In a mouse model with gastric peri-
toneal metastases, retarded tumor growth and development 
of malignant ascites were demonstrated after being treated 
with bevacizumab.77
Shah and colleagues conducted a phase II trial to evaluate 
the efficacy and safety of adding bevacizumab to irinotecan/
cisplatin combination in metastatic or unresectable gastric 
and gastroesophageal (GE) junction adenocarcinoma.78 This 
is a multicenter trial that enrolled 47 patients. The dose and 
schedule were: bevacizumab 15 mg/kg on day 1, irinotecan 
65 mg/m2, and cisplatin 30 mg/m2 on days 1 and 8 every 
21 days. With a median follow-up of 12.2 months, this 
combination regimen achieved overall RR of 65% (95% CI 
46% to 80%), median TTP of 8.3 months (95% CI 5.5 to 
9.9), and median OS of 12.3 months (95% CI 11.3 to 17.2), 
suggesting a 75% improvement compared with historical 
control. Toxicity profile was not different from other 
bevacizumab-containing regimens, including hypertension, 
GI perforation, GI bleeding, and thromboembolic events. 
Table 7 Ongoing clinical trials investigating bevacizumab for biliary duct carcinoma and gallbladder cancer
Phase Condition Intervention and schedule Projected 
accural
Investigator
ii Cholangiocarcinoma, Gallbladder 
cancer
erlotinib 150 mg daily, bevacizumab 
10 mg/kg q14d
126 rigshospitalet, 
Denmark
ii extrahepatic bile duct cancer, 
gallbladder cancer
Erlotinib daily bevacizumab q14d  
(dose not specified)
55 Mayo Clinic
i Hepatocellular carcinoma, 
cholangiocarcinoma
Proton radiotherapy 3 Gy per fraction × 20, 
bevacizumab 10 mg/kg q14d
30 MD Anderson
ii Billiary tract adenocarcinoma, 
Gallbladder adenocarcinoma
Gemcitabine q14d oxaliplatin q14d 
bevacizumab q14d (dose not specified)
37 MGH
ii Biliary tract cancer, Gallbladder 
adenocarcinoma
Capecitabine oxaliplatin bevacizumab 
q14d Radiation therapy for total  
28 treatments (dose not specified)
26 MGH
Notes:   Adapted from www.clinicaltrials.gov.
Abbreviations: MGH, Massachusetts General Hospital; 5-FU/LV, fluouracil and leucovorin; FOLFOX, 5-FU/LV/oxaliplatin; mFOLFOX, modified FOLFOX; FOLFIRI, 5-FU/LV/
irinotecan; CapeOX, capecitabine/oxaliplatin; IFL, irinotecan, 5-FU, and LV; mIFL, bolus IFL.Biologics: Targets & Therapy 2009:3 438
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Further optimization of the use of bevacizumab in gastric 
and GE junction cancers is warranted.
Two abstracts presented at the 2009 ASCO annual 
meeting are worth discussing.79,80 Based on the data obtained 
in the Shah phase II study, Kelsen and colleagues investigated 
modified docetaxel, cisplatin, fluorouracil (mDCF), and 
bevacizumab in metastatic GE junction adenocarcinoma as 
first-line therapy.79 The primary objective was to improve 
6-month PFS from 43% (historical DCF control) to 63% 
with the addition of bevacizumab. Thirty-nine of 44 eligible 
patients had measurable disease. Overall RR was 67% (95% 
CI 50% to 81%), 6-month PFS was 79% (95% CI 68% to 
93%), median PFS was 12 months (95% CI 8.8 to 16), and 
median OS was 16.2 months (95% CI 11.4 to infinitiy) after 
a median follow-up of 12.3 months. This bevacizumab-
containing regimen provided a durable survival benefit 
without significant toxicities.
A similar regimen with docetaxel and oxaliplatin in 
combination with bevacizumab was investigated by El-Raves 
and colleagues.80 The primary endpoint was TTP. A total of 
23 patients with locally advanced or metastatic gastric/GE 
junction cancer were enrolled. PR was confirmed in 10 (59%) 
patients. However, in contrast to the safety report of the 
other mDCF plus bevacizumab trial, 3 GI perforations was 
reported in this trial. This alerted the investigators not to 
use bevacizumab outside clinical trials until more safety 
data are obtained.
Neuroendocrine tumors (NET)
Neuroendocrine tumors, also named gastroenteropancreatic 
NET (GEP-NET), are cancers arising from endocrine (hor-
monal) system and the nervous system. There are essen-
tially two distinct categories: functional or secretory, and 
nonfunctional tumors. Secretory NETs are usually treated 
with somatostatin analog-based therapy such as octreotide 
for symptomatic control. In metastatic stage, chemotherapy 
generally has low response rate with short duration.
Chemotherapeutic agents tested in locoregionally 
advanced or metastatic NETs include doxorubicin, 
capecitabine, oxaliplatin, streptozocin, 5-FU, temozolomide, 
and dacarbazine as single agents or in combination. Early 
data suggest that single-agent bevacizumab for advanced 
carcinoid tumors inhibits tumor blood flow and increases 
PFS.81 At the 2008 ASCO annual meeting, Kunz and 
colleagues presented the interim analysis of a phase II trial 
investigating a combination of capecitabine, oxaliplatin, 
and bevacizumab for metastatic/unresectable NETs.82 This 
is a relatively well tolerated regimen for CRC. The primary 
endpoints were to determine median TTP and assess the 
toxicities associated with this regimen. Among 13 patients 
of a planned 37, 4 achieved a PR with durations of 33, 27+, 
27+, 27+ weeks, respectively. Toxicities were expected to 
be related to chemotherapeutic agents.
The Dana-Farber cancer institute also conducted a 
phase II trial to investigate the efficacy of bevacizumab in 
combination with temozolomide in advanced NET.83 This 
was a nonrandomized, open label, single-arm study. The 
primary endpoint was to assess the response to bevacizumab 
and temozolomide in metastatic NET. Secondary endpoints 
were assess TTP, PFS, and safety of this combination. 
The schedule of temozolomide was once daily for 1 week 
followed by 1 week off. Bevacizumab was given intrave-
nously every 2 weeks. Restaging CT scan was performed 
every 8 weeks to assess response. Among 29 evaluable 
patients for efficacy, 4 achieved PR, which made the response 
rate of 24%. Bevacizumab-related toxicities were not severe 
except one patient developed hypertension.
The question of whether octreotide has an anti-tumor 
effect in addition to symptomatic control was answered at 
the 2009 GI ASCO meeting.84 PROMID (Placebo-controlled 
prospective Randomized study on the antiproliferative 
efficacy of Octreotide LAR in patients with metastatic 
neuroendocrine MIDgut tumors) was the first randomized, 
double-blind, placebo-controlled, multicenter, phase IIIb 
study of long-acting release (LAR) octreotide in patients with 
metastatic NETs.84 Eighty-five eligible patients randomly 
received either octreotide LAR or placebo. Octreotide LAR 
significantly lengthened median TTP from 6 months in the 
placebo groups to 14.3 months (HR 0.34; 95% CI 0.20 to 
0.59; P = 0.000072). Therefore, a trial to test bevacizumab 
and octreotide combination in metastatic NETs would be 
the next step.
Future directions
Bevacizumab has provided the proof of concept that 
angiogenesis is an important target for cancer therapy and 
is the first anti-VEGF monoclonal antibody to receive FDA 
approval. Bevacizumab has shown clinical efficacy in a 
variety of advanced malignancies including CRC, nonsmall 
cell lung cancer, breast cancer, kidney cancer, ovarian 
epithelial cancer, and hepatocellular carcinoma.
Although bevacizumab has an established role in the treat-
ment of metastatic colon, breast, and lung cancer, but many 
questions remain about its use in other disease types and 
demographic groups. Future studies are designed to evaluate. 
Important questions in treatment of advanced cancers are the Biologics: Targets & Therapy 2009:3 439
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optimal dose and duration of treatment with bevacizumab. 
One of the main aims of the ongoing CAIRO3 trial is to 
investigate the possible benefit of maintenance therapy with 
bevacizumab and low-dose capecitabine after initial therapy 
with chemotherapy and bevacizumab in mCRC. Resolution 
of the question abut optimal dose, however, has become 
increasingly challenging, and it is the opinion of the authors 
that a determination of optimal duration is likely to have the 
greater effect on outcomes.
Biomarker studies are crucial in identifying patients 
who would most benefit from bevacizumab therapy. The 
ECOG 5202 trial is a unique ongoing phase III prospective 
study aimed at determining the role of chemotherapy in 
stage II colon cancer patients by assigning treatment base 
risk as determined by molecular profiling. Patients will be 
stratified to ‘high risk’ or ‘low risk’ based on microsatellite 
instability and loss of heterozygosity at 18q. Patients deemed 
to be ‘high risk’ will be randomized to 5-FU/LV/oxaliplatin 
versus 5-FU/LV/oxaliplatin plus bevacizumab. Those patients 
deemed to be ‘low risk’ will be registered for observation 
only. Thus, identifying criteria for individualized treatment 
with bevacizumab may not only improve efficacy but, through 
better patient selection, could also limit the use of expensive 
therapies in populations not likely to benefit from them.
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